A bacterial population regulator for promoting the bacterial population of Staphylococcus hominis

Abstract

To provide a bacterial volume controlling agent for promoting a bacterial volume of Staphylococcus hominis.SOLUTION: The agent contains Panax ginseng extract and / or Citrus unshiu peel extract as an active ingredient.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a bacterial load regulator for promoting the bacterial load of Staphylococcus hominis. [Background technology]

[0002] In recent years, cosmetics containing, as an active ingredient, bacterial cells having beneficial effects on the human body have been proposed (Patent Document 1). For example, Patent Document 2 discloses the use of Staphylococcus hominis as an active ingredient in the treatment of atopic dermatitis.

[0003] Additionally, technology that specifically controls certain bacteria that have a beneficial effect on skin conditions is also attracting attention.

[0004] Incidentally, as a conventional technique, Patent Document 3 discloses a skin barrier function enhancer that contains a Panax ginseng (Korean ginseng) extract.

[0005] Furthermore, Patent Document 4 discloses that Citrus unshiu Mare. has the effect of whitening the skin and reducing pigmentation caused by exposure to artificial or natural ultraviolet rays.

[0006] Furthermore, Patent Document 5 discloses an external skin preparation for acne-prone skin that contains Citrus unshiu peel.

[0007] Furthermore, as an external skin composition that combines the above-mentioned plant extract with sugars, Patent Document 6 discloses an external skin composition that contains ginseng (Korean ginseng) and trehalose.

[0008] Furthermore, Patent Document 7 discloses a composition comprising an extract of ginseng from the Araliaceae family (Korean ginseng) and a cyclodextrin compound.

[0009] Moreover, Patent Document 8 discloses an external skin preparation containing Citrus unshiu extract and oligosaccharides. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] Japanese Patent Application Publication No. 09-020638 [Patent Document 2] Special Publication No. 2018-515488 [Patent Document 3] JP 2015-105268 A [Patent Document 4] Special Publication No. 2004-506677 [Patent Document 5] International Publication No. 2009 / 084200 Brochure [Patent Document 6] JP 2008-208118 A [Patent Document 7] Japanese Patent Application Publication No. 11-290024 [Patent Document 8] JP 2007-204449 A Summary of the Invention [Problem to be solved by the invention]

[0011] In view of the above-mentioned prior art, an object of the present invention is to provide a novel technique for specifically controlling the amount of a specific bacterial cell.

[0012] As a result of intensive research efforts, the present inventors have found that Korean ginseng extract and / or Chinese chimpi extract have an effect of promoting the bacterial count of Staphylococcus hominis, and have completed the present invention. [Means for solving the problem]

[0013] The present invention, which solves the above problems, provides a bacterial count regulator for promoting the bacterial count of Staphylococcus hominis, comprising a ginseng extract and / or a chinpi extract.

[0014] A preferred embodiment of the present invention is characterized in that it comprises a combination of two or more selected from the group consisting of ginseng extract, tangerine peel extract, and ginger extract.

[0015] In a preferred embodiment of the present invention, the bacterial amount regulator is Korean ginseng extract and / or chinpi extract, and Contains as an active ingredient It is a bacterial volume regulator for promoting the bacterial volume of Staphylococcus hominis and suppressing the bacterial volume of Staphylococcus aureus.

[0016] In a preferred embodiment of the present invention, the bacterial amount regulator is Korean ginseng extract and / or chinpi extract, Xylitol and Contains as an active ingredient It is a bacterial load regulator for promoting the bacterial load of Staphylococcus hominis and suppressing the bacterial load of Staphylococcus aureus and / or Propionibacterium acnes.

[0017] In this specification, the concept of "promoting bacterial count" includes both increasing the bacterial count and inhibiting a decrease in the bacterial count, and the concept of "inhibiting bacterial count" includes both decreasing the bacterial count and inhibiting an increase in the bacterial count.

[0018] In a preferred embodiment of the present invention, the bacterial load regulator is a composition for external application to the skin.

[0019] The present invention also relates to a method for producing a ginseng extract and / or a chinpi extract, Xylitol and It is also a composition for external use on the skin, characterized by comprising:

[0020] The present invention also relates to a method for producing a ginseng extract and / or a chinpi extract, and It is also a composition for external use on the skin, characterized by comprising:

[0021] In a preferred embodiment of the present invention, the above-mentioned composition for external application to the skin is intended to prevent or improve skin conditions based on an increase in the number of noticeable pores and / or an increase in the amount of melanin, and the number of wrinkles.

[0022] In a preferred embodiment of the present invention, the above-mentioned external skin composition is used for one or more of the following: rough skin, increased sebum production, spots, dullness, pigmentation, and wrinkles.

[0023] In a preferred embodiment of the present invention, the composition for external application to the skin is a cosmetic.

[0024] In a preferred embodiment of the present invention, the above-mentioned composition for external application to the skin is a pharmaceutical product. Effect of the Invention

[0025] According to the present invention, an agent having excellent bacterial quantity promoting effect on Staphylococcus hominis can be provided. Furthermore, according to a preferred embodiment of the present invention, an agent having excellent effects of promoting the bacterial count of Staphylococcus hominis and suppressing the bacterial count of Staphylococcus aureus and / or Propionibacterium acnes can be provided. [Brief description of the drawings]

[0026] [Figure 1] 1 is a graph showing the results of Test Example 1. [Diagram 2] 1 is a graph showing the results of a reference test example. [Diagram 3] 1 is a graph showing the results of Test Example 2. [Figure 4] 1 is a graph showing the results of Test Example 3. [Diagram 5] 1 is a graph showing the results of Test Example 4. [Figure 6] 1 is a graph showing the results of Test Example 5. [Figure 7] 1 is a graph showing the results of Test Example 6. [Figure 8] <Example 3> Graph showing the results of the amount of S. hominis in the application test. [Figure 9] <Example 3> Graph showing the results of the amount of S. aureus in the coating test. [Figure 10] <Example 3> A graph showing the results of the amount of P. acnes in the application test. [Figure 11] <Example 4> This is a graph showing the results of the amount of Staphylococcus hominis (S. hominis) in a verification test for the relationship between parameters related to skin condition and S. hominis. [Figure 12] <Example 4> This is a diagram showing the results of the change in the number of noticeable pores in a verification test of the association between parameters related to skin condition and Staphylococcus hominis (S. hominis). [Figure 13] <Example 4> This is a diagram showing the results of the change in melanin index in a verification test of the association between parameters related to skin condition and Staphylococcus hominis (S. hominis). [Figure 14]<Example 4> A diagram showing the results of the change in the number of wrinkles in a verification test of the association between parameters related to skin condition and Staphylococcus hominis (S. hominis). [Figure 15] 1 is a graph showing the results of changes in the amount of Staphylococcus aureus when the herbaceous extract of <Example 5> is used alone. [Figure 16] 1 is a graph showing the results of changes in the amount of Staphylococcus hominis (S. hominis) due to the combination of ginseng extract (ginseng LAH2A) and Galium arbutifolia extract in <Example 6>. [Figure 17] 1 is a graph showing the results of changes in the amount of Staphylococcus hominis (S. hominis) due to the combination of Citrus Fruit Extract and Scutellaria Baicalensis Extract in <Example 6>. [Figure 18] 1 is a graph showing the results of changes in the amount of Staphylococcus hominis (S. hominis) due to a combination of ginseng extract (ginseng extract) and Galium arbutifolia extract in <Example 6>. [Figure 19] 1 is a graph showing the transitional results of the amount of Staphylococcus aureus by the combination of Korean ginseng extract (ginseng LAH2A) and Asiatica extract in <Example 6>. [Figure 20] 1 is a graph showing the results of changes in the amount of Staphylococcus aureus due to the combination of Citrus Fruit Pepper extract and Citrus Fruit Extract in <Example 6>. [Figure 21] 1 is a graph showing the results of changes in the amount of Staphylococcus aureus due to a combination of ginseng extract (ginseng extract) and Galium arbutifolia extract in <Example 6>. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0027] The bacterial count regulator for promoting the bacterial count of Staphylococcus hominis of the present invention comprises a Korean ginseng extract and / or a Chinese chimpi extract.

[0028] Here, in the present invention, it is preferable to use a combination of two or more selected from Korean ginseng extract, Chinese chimpi extract, and Chinese laurel extract.

[0029] Korean ginseng extract can be produced by extracting Korean ginseng and / or Chinese ginseng grown wild or cultivated in Japan. Alternatively, commercially available Korean ginseng extract and / or Chinese chimpi extract sold by a company dealing in plant raw materials can be purchased and used.

[0030] The ginseng extract may be purchased and used from a commercially available company that handles plant raw materials. In addition, ginseng extract can be produced by extracting the roots of ginseng that grows wild or is grown in Japan.

[0031] When extracting ginseng extract, it is preferable to process ginseng roots in advance by crushing or cutting them into small pieces so as to improve the extraction efficiency.

[0032] The extract can be obtained by the following method. 1 to 30 parts by mass of a solvent is added to 1 part by mass of ginseng root or its dried product, and the mixture is immersed for several days at room temperature or for several hours at a temperature near the boiling point. After immersion, the mixture is cooled to room temperature, and insoluble matter is removed as desired, followed by removal of the solvent by vacuum concentration or the like. The mixture is then fractionated and purified by column chromatography packed with silica gel or ion exchange resin to obtain the desired extract.

[0033] The extraction solvent is preferably a polar solvent, and suitable examples thereof include one or more selected from water, alcohols such as ethanol, isopropyl alcohol, and butanol, polyhydric alcohols such as 1,3-butanediol and polypropylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran. Among these, ethanol is a preferred extraction solvent.

[0034] The extract of Citrus unshiu can be purchased and used from a commercially available company that deals in plant raw materials. Furthermore, Chinpi extract can be prepared by extracting the peel of a citrus plant (e.g., mandarin orange) that grows wild or is cultivated in Japan.

[0035] In addition, when extracting Citrus Fruit Extract, it is preferable to previously process the peel of the Rutaceae plant by crushing or cutting it into small pieces so as to improve the extraction efficiency.

[0036] The extract can be obtained by the following method. 1 to 30 parts by mass of a solvent is added to 1 mass of the peel of a citrus plant or its dried product, and the mixture is immersed for several days at room temperature or for several hours at a temperature near the boiling point. After immersion, the mixture is cooled to room temperature, and insoluble matter is removed as desired, and then the solvent is removed by concentrating under reduced pressure or the like. The mixture is then fractionated and purified by column chromatography filled with silica gel or ion exchange resin to obtain the desired extract.

[0037] The extraction solvent is preferably a polar solvent, and suitable examples thereof include one or more selected from water, alcohols such as ethanol, isopropyl alcohol, and butanol, polyhydric alcohols such as 1,3-butanediol and polypropylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran. Among these, ethanol is a preferred extraction solvent.

[0038] The tallow tree extract can be prepared by extracting tallow tree that grows wild or is grown in Japan. Alternatively, commercially available Thamnoides extracts sold by companies dealing in plant raw materials can be purchased and used.

[0039] When extracting the tallow extract, it is preferable to previously process the tallow fruit by crushing or cutting it into small pieces so as to improve the extraction efficiency.

[0040] The extract can be obtained by the following method. 1 to 30 parts by mass of a solvent is added to 1 part by mass of the fruit of the marigold or its dried matter, and the mixture is immersed for several days at room temperature or for several hours at a temperature near the boiling point. After immersion, the mixture is cooled to room temperature, and insoluble matter is removed as desired, and then the solvent is removed by, for example, concentrating under reduced pressure. Thereafter, the mixture is fractionated and purified by, for example, column chromatography filled with silica gel or ion exchange resin to obtain the desired extract.

[0041] The extraction solvent is preferably a polar solvent, and suitable examples thereof include one or more selected from water, alcohols such as ethanol, isopropyl alcohol, and butanol, polyhydric alcohols such as 1,3-butanediol and polypropylene glycol, ketones such as acetone and methyl ethyl ketone, and ethers such as diethyl ether and tetrahydrofuran. Among these, ethanol is a preferred extraction solvent.

[0042] The content of ginseng extract and / or Citrus grandis extract in the bacterial mass regulator of the present invention is preferably 0.02 mass% or more, more preferably 0.05 mass% or more, even more preferably 0.08 mass% or more, and particularly preferably 0.1 mass% or more. The content of the Korean ginseng extract and / or the Citrus unshiu extract is 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1.2% by mass or less.

[0043] The content of Thamnoides extract in the bacterial mass regulator of the present invention is preferably 0.02 mass % or more, more preferably 0.05 mass % or more, even more preferably 0.08 mass % or more, and particularly preferably 0.1 mass % or more. The content of the tallow extract is 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1.2% by mass or less.

[0044] In the present invention, it is preferred to use a combination of a ginseng extract and / or a Citrus Pepper extract and an Asiatic Rhizome extract. By combining the Korean ginseng extract and / or the Citrus unshiu extract with the Tibetan ginseng extract, it is possible to specifically control the amount of a specific fungus. More specifically, by combining Korean ginseng extract and / or Chinese cabbage extract with Chinese herb extract, it is possible to simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus.

[0045] The content ratio of the ginseng extract and the Arena officinalis extract in the bacterial quantity regulator of the present invention is preferably 1:1.5 to 1:0.5, more preferably 1:1.2 to 1:0.8. The content ratio of Citrus Fruit Extract and Citrus Fruit Extract in the bacterial quantity regulator of the present invention is preferably 1:2 to 1:0.5, more preferably 1:1.5 to 1:0.5, and even more preferably 1:1.2 to 1:0.8.

[0046] By setting the content of the Korean ginseng extract and / or the Citrus unshiu extract and the Tibetan ginseng extract within the above ranges, the amount of the specific fungus can be specifically controlled. More specifically, by setting the content of Korean ginseng extract and / or Chinese cabbage extract and Chinese laurel extract within the above ranges, it is possible to simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus.

[0047] In the present invention, it is preferable to use a combination of a ginseng extract and / or a Citrus Fruit Extract with xylitol. By combining the Korean ginseng extract and / or the Citrus unshiu extract with xylitol, the amount of a specific bacterial cell can be specifically controlled. More specifically, by combining a Korean ginseng extract and / or a Chinese chimpi extract with xylitol, it is possible to simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus and / or Propionibacterium acnes.

[0048] The xylitol content in the bacterial mass regulator of the present invention is preferably 0.5% by mass or more, and more preferably 0.8% by mass or more. The xylitol content in the bacterial mass regulator of the present invention is 2 mass % or less, preferably 1.5 mass % or less, and more preferably 1.2 mass % or less.

[0049] The content ratio of the ginseng extract to xylitol in the bacterial quantity regulator of the present invention is preferably 1:1.5 to 1:0.5, and more preferably 1:1.2 to 1:0.8. The content ratio of Citrus unshiu extract to xylitol in the bacterial quantity regulator of the present invention is preferably 1:2 to 1:0.5, more preferably 1:1.5 to 1:0.5, and even more preferably 1:1.2 to 1:0.8.

[0050] By adjusting the content of the ginseng extract and / or the Citrus unshiu extract and xylitol to fall within the above ranges, the amount of a specific fungus can be specifically controlled. More specifically, by adjusting the content of Korean ginseng extract and / or Chinese cabbage extract and xylitol to the above ranges, it is possible to simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus and / or Propionibacterium acnes.

[0051] The bacterial load regulator of the present invention may be in the form of a composition for external application to the skin or a composition for oral administration. In particular, the bacterial load regulator of the present invention is preferably in the form of a composition for external application to the skin.

[0052] Suitable examples of skin external compositions include cosmetics and pharmaceuticals.

[0053] Among these, it is preferable that the composition is in the form of a cosmetic preparation that can be used continuously, for example, a lotion, milky lotion, beauty essence, cream, gel, sun care product, or the like.

[0054] The content of ginseng extract and / or Citrus Pepper extract in the composition for external use on the skin is 0.05% by mass or more, preferably 0.08% by mass or more, and more preferably 0.1% by mass or more. The content of ginseng extract and / or Citrus unshiu extract in the composition for external use on skin is 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1.2% by mass or less.

[0055] The content of the Thamnoides extract in the composition for external use on the skin is 0.05% by mass or more, preferably 0.08% by mass or more, and more preferably 0.1% by mass or more. The content of the Thamnoides extract in the composition for external use on skin is 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1.2% by mass or less.

[0056] The content of xylitol in the composition for external use on skin is preferably 0.5% by mass or more, and more preferably 0.8% by mass or more. The content of xylitol in the composition for external use on skin is 2% by mass or less, preferably 1.5% by mass or less, and more preferably 1.2% by mass or less.

[0057] By adjusting the content of the ginseng extract and / or the Citrus unshiu extract and xylitol to fall within the above ranges, the amount of a specific fungus can be specifically controlled. More specifically, by adjusting the content of Korean ginseng extract and / or Chinese cabbage extract and xylitol to the above ranges, it is possible to simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus and / or Propionibacterium acnes.

[0058] Furthermore, by setting the contents of the Korean ginseng extract and / or the Citrus Pepper extract and the Asiatic Prickly Pear extract within the above ranges, the amount of a specific fungus can be specifically controlled. More specifically, by setting the content of Korean ginseng extract and / or Chinese cabbage extract and Chinese laurel extract within the above ranges, it is possible to simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus.

[0059] It is known that atopic dermatitis can be improved by promoting the bacterial count of Staphylococcus hominis. Furthermore, as shown in the examples described later, by promoting the amount of Staphylococcus hominis bacteria, it is possible to prevent or improve skin conditions based on any one of the following: an increase in the number of noticeable pores, an increase in the amount of melanin, or an increase in the number of wrinkles.

[0060] Here, examples of skin conditions caused by an increase in the number of noticeable pores include rough skin and increased sebum production. In addition, skin conditions caused by increased amounts of melanin include age spots, dullness, pigmentation, post-inflammatory pigmentation, and solar pigmentation. Furthermore, an example of a skin condition caused by an increase in the number of wrinkles is wrinkles.

[0061] It is also known that atopic dermatitis can be improved by suppressing the amount of Staphylococcus aureus bacteria.

[0062] It is also known that acne can be improved by suppressing the amount of Propionibacterium acnes.

[0063] Therefore, by using a combination of ginseng extract and / or tangerine extract, and further xylitol, it is possible to provide a topical skin composition which specifically controls the amount of the above-mentioned bacterial cells and exerts the above-mentioned skin condition improving effect in a complex manner.

[0064] Furthermore, by using a combination of Korean ginseng extract and / or Chinese ginger extract, and further an extract of Chinese laurel wort, it is possible to provide a topical skin composition which specifically controls the amount of the above-mentioned fungal bodies and exerts the above-mentioned skin condition improving effect in a complex manner.

[0065] When the composition is provided in the form of a skin external composition, its composition is not particularly limited, and it can contain any optional ingredient that is usually used, as long as it does not impair the effect of the present invention.Such optional ingredients include, for example, oils and waxes such as macadamia nut oil, avocado oil, corn oil, olive oil, rapeseed oil, sesame oil, castor oil, safflower oil, cottonseed oil, jojoba oil, coconut oil, palm oil, liquid lanolin, hydrogenated coconut oil, hydrogenated oil, Japan wax, hydrogenated castor oil, beeswax, candelilla wax, carnauba wax, ivotaro wax, lanolin, reduced lanolin, hard lanolin, and jojoba wax; liquid paraffin, squalane, pristane, ozokerite, paraffin, ceresin, petrolatum, micelle, and the like. Hydrocarbons such as locrystalline wax; higher fatty acids such as oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, and undecylenic acid; higher alcohols such as cetyl alcohol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, octyldodecanol, myristyl alcohol, and cetostearyl alcohol; cetyl isooctanoate, isopropyl myristate, hexyldecyl isostearate, diisopropyl adipate, sebacic acid, and the like; synthetic ester oils such as di-2-ethylhexyl phosphate, cetyl lactate, diisostearyl malate, ethylene glycol di-2-ethylhexanoate, neopentyl glycol dicaprate, glycerin di-2-heptylundecanoate, glycerin tri-2-ethylhexanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, pentane erythritol tetra-2-ethylhexanoate, and other oils; fatty acid soaps (sodium laurate, sodium palmitate, etc.); anionic surfactants such as potassium lauryl sulfate, alkyl sulfate triethanolamine ether; cationic surfactants such as stearyltrimethylammonium chloride, benzalkonium chloride, laurylamine oxide; amphoteric surfactants such as imidazoline-based amphoteric surfactants (2-cocoyl-2-imidazolinium hydroxide-1-carboxyethyloxy disodium salt, etc.), betaine-based surfactants (alkyl betaine, amido betaine, sulfo betaine, etc.), and acyl methyl taurine;Sorbitan fatty acid esters (sorbitan monostearate, sorbitan sesquioleate, etc.), glycerin fatty acids (glycerin monostearate, etc.), propylene glycol fatty acid esters (propylene glycol monostearate, etc.), hydrogenated castor oil derivatives, glycerin alkyl ethers, POE sorbitan fatty acid esters (POE sorbitan monooleate, polyoxyethylene sorbitan monostearate, etc.), POE sorbitol fatty acid esters (POE-sorbitol monolaurate, etc.), POE glycerin fatty acid esters (POE-glycerin monoisostearate, etc.), POE fatty acid esters (polyethylene glycol monooleate, POE distearate, etc.), POE alkyl ethers (POE 2-octyldodecyl ether, etc.), POE alkyl phenyl ethers (POE nonylphenyl ether, etc.), Pluronic types, POE Preferred examples of the surfactants include nonionic surfactants such as POP alkyl ethers (POE POP 2-decyltetradecyl ether, etc.), tetronics, POE castor oil / hydrogenated castor oil derivatives (POE castor oil, POE hydrogenated castor oil, etc.), sucrose fatty acid esters, and alkyl glucosides; polyhydric alcohols such as polyethylene glycol, glycerin, erythritol, sorbitol, maltitol, propylene glycol, and 2,4-hexanediol; moisturizing ingredients such as sodium pyrrolidone carboxylate, lactic acid, and sodium lactate; para-aminobenzoic acid-based ultraviolet absorbers; anthranilic acid-based ultraviolet absorbers; salicylic acid-based ultraviolet absorbers; cinnamic acid-based ultraviolet absorbers; benzophenone-based ultraviolet absorbers; sugar-based ultraviolet absorbers; and ultraviolet absorbers such as 2-(2'-hydroxy-5'-t-octylphenyl)benzotriazole and 4-methoxy-4'-t-butyldibenzoylmethane.

[0066] When the composition is prepared as an oral composition, it is preferable to prepare a food composition containing the active ingredient of the present invention. Specifically, the composition may be in the form of a supplement having the dosage form of a general food, tablet, granule, drink, or the like.

[0067] Here, the contents and content ratios of ginseng extract and / or Citrus Pepper extract in the oral composition can be applied mutatis mutandis to the descriptions of the preferred embodiments of the topical skin composition described above.

[0068] In addition, the content and content ratio of the Thamnoides extract in the oral composition can be applied mutatis mutandis to the description of the preferred embodiment of the composition for external use on the skin described above.

[0069] When the composition is prepared as an oral composition, any optional ingredient may be appropriately blended within a range that does not impair the effects of the present invention.

[0070] The present invention may also be in the form of a kit comprising a composition containing a ginseng extract and / or a Citrus unshiu extract, and a composition containing xylitol. In a kit containing a composition containing ginseng extract and / or tangerine peel extract and a composition containing xylitol, the above-mentioned items can be applied to the content of each active ingredient when the composition containing ginseng extract and / or tangerine peel extract and the composition containing xylitol are mixed.

[0071] The present invention may also be in the form of a kit comprising a composition containing a ginseng extract and / or a Citrus Pepper extract, and a composition containing a Salvia gracilis extract. The above description can be applied to a preferred embodiment of a kit comprising a composition containing a ginseng extract and / or a Citrus Pepper extract and a composition containing a Thamnoides extract.

[0072] The present invention can also provide a method for adjusting the amount of bacteria on the skin, which comprises applying a ginseng extract and / or a Citrus Pepper extract and xylitol to the skin.

[0073] Here, the method for controlling the amount of bacteria on the skin of the present invention is a non-therapeutic method, preferably a cosmetic method, more preferably a cosmetic method for the skin.

[0074] According to the method for regulating the amount of bacteria on the skin of the present invention, the amount of a specific bacteria can be specifically controlled. More specifically, by applying a Korean ginseng extract and / or a Chinese chimpi extract and xylitol to the skin, it is possible to promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus and / or Propionibacterium acnes. According to the method of the present invention, by applying ginseng extract and / or tangerine extract and xylitol to the skin and adjusting the amount of bacteria as described above, it is possible to more effectively prevent or improve skin conditions caused by any of the following: an increase in the number of noticeable pores, an increase in the amount of melanin, or an increase in the number of wrinkles.

[0075] More specifically, according to the method of the present invention, by applying Korean ginseng extract and / or Chinese ginger extract and xylitol to the skin and adjusting the amount of bacteria as described above, it is possible to prevent or improve rough skin, increased sebum production, age spots, dullness, pigmentation, post-inflammatory pigmentation, solar pigmentation, and wrinkles.

[0076] The present invention can also provide a method for adjusting the amount of bacteria on the skin, which comprises applying a ginseng extract and / or a Citrus Pepper extract and an Arenia extract to the skin. The above explanation can be applied to a preferred embodiment of the method for adjusting the amount of bacteria on the skin, which is characterized by applying a ginseng extract and / or a Chinese ginseng extract and an Asian laurel extract to the skin.

[0077] The above-mentioned contents can be applied to the preferred embodiment of the method for adjusting the amount of bacteria on the skin of the present invention. EXAMPLES

[0078] Below, the bacterial quantity adjusting ability was examined when ginseng extract and / or Citrus unshiu extract was combined with xylitol.

[0079] <Example 1> Test of changes in bacterial count with the combination of ginseng extract and xylitol (1) Test Example 1: Examination of changes in the amount of Staphylococcus hominis

[0080] (1-1) Preparation of bacterial suspension First, Staphylococcus hominis GTC485 strain (hereinafter, simply referred to as S. hominis) was cultured under aerobic conditions at 37°C using 802 medium (see the table below) at pH 7.0. Here, the Staphylococcus hominis GTC485 strain was purchased through the Japanese Society for Bacteriology (Postal Code: 170-0003, Address: Komagome TS Building, 1-43-9 Komagome, Toshima-ku, Tokyo, Japan (Oral Health Association).

[0081] The OD660 of the cultured bacterial suspension was measured using a turbidity meter (NovaspecII (Amercham Pharmacia Biotech)), and the bacterial concentration was calculated.

[0082] (1-2) Test method and results The bacterial suspension prepared by the above-mentioned method was added to the example medium shown in Table 1 (Table 1, Example 1) and the comparative example medium (Table 1, Comparative Example 1) so that the total volume was 5 mL. The amount of bacteria in the medium after adding bacteria was 5 × 10 7 cells.

[0083] [Table 1]

[0084] After the addition, shaking culture was carried out under aerobic conditions at 37°C.

[0085] From the start of the shaking culture, OD660 was measured every hour using a turbidity meter (NovaspecII (Amercham Pharmacia Biotech)). The change in OD660 measurement value (OD660Δinitial value) was calculated by subtracting the OD660 measurement value at the measured time from the OD660 measurement value at the start of shaking culture.

[0086] (1-3) Reference test example: Examination of the effects of Korean ginseng extract Except for changing the test medium to the comparative example medium (Table 1 Comparative Example 1) and the reference example medium (Table 1 Reference Example 1), the same method as described above in (1) was used to verify the change in the amount of Staphylococcus hominis. The change in OD660 measurement value (OD660Δinitial value) was calculated by subtracting the OD660 measurement value at the measured time from the OD660 measurement value at the start of shaking culture.

[0087] (2) Test Example 2: Changes in the amount of Staphylococcus aureus Furthermore, a test was also conducted using the same method as above to monitor the change in the amount of Staphylococcus aureus (Test Example 2). Here, the Staphylococcus aureus ATCC6538 strain (hereinafter, simply referred to as S. aureus) was used as the Staphylococcus aureus. Here, the Staphylococcus aureus ATCC6538 strain was purchased through the National Institute of Technology and Evaluation (Postal Code: 292-0818, Address: 2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture).

[0088] The change in OD660 measurement value (OD660Δinitial value) was calculated by subtracting the OD660 measurement value at the measured time from the OD660 measurement value at the start of shaking culture.

[0089] The results are shown in Table 2 and Figure 1. The results were expressed as the mean ± standard deviation (sd) of N=3. Statistical analysis was performed based on the t-test (*P<0.05).

[0090] [Table 2]

[0091] (3) Propionibacterium acnes culture test

[0092] (3-1) Preparation of bacterial suspension First, Propionibacterium acnes was cultured under anaerobic conditions at 37°C using GAM medium at pH 7.0 (see Table 3 below). Here, Propionibacterium acnes ATCC6919 strain (hereinafter, simply referred to as P. acnes) was used as Propionibacterium acnes. Here, Propionibacterium acnes ATCC6919 strain was purchased from Sumitomo Pharma International Co., Ltd. (Postal Code: 100-0003, Address: Sumitomo Corporation Takebashi Building 12F, 2-2 Hitotsubashi 1-chome, Chiyoda-ku, Tokyo).

[0093] (3-2) Test methods and results The bacterial suspension prepared by the above-mentioned method was transferred to 10 mL of the example medium (Example 3) and 10 mL of the comparative example medium (Comparative Example 3) shown in the table. Here, in order to eliminate the influence of other sugars, a medium in which sugars were removed from GAM medium (sugar-free medium) was used as the example medium and the comparative medium.

[0094] [Table 3]

[0095] The bacterial concentration of the prepared bacterial suspension was calculated using a hemocytometer, diluted with physiological saline, and then diluted to 1 × 10 8 A CFU / mL bacterial solution was prepared.

[0096] The OD660 was measured 16 hours, 20 hours, and 24 hours after the start of culture in 10 mL of example medium (Example 3) and 10 mL of comparative example medium (Comparative Example 3) using a turbidity meter (absorbance meter).

[0097] The results are shown in Table 4 and Figure 4. The change in OD660 measurement value (OD660Δinitial value) was calculated by subtracting the OD660 measurement value at the measurement time from the OD660 measurement value at the start of culture. The results were expressed as the mean ± standard deviation (sd) of N=3. Statistical analysis was performed based on the t-test (*P<0.05).

[0098] [Table 4]

[0099] (4) Discussion From the results in Tables 2 and 4 of Example 1, it was found that the amount of a specific bacterial cell can be specifically controlled by using a combination of ginseng extract and xylitol. More specifically, it was found that the combined use of ginseng extract and xylitol can simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus and / or Propionibacterium acnes.

[0100] In addition, a comparison of the results of Test Example 1 and the Reference Test Example revealed that ginseng extract has a bacterial count promoting effect on Staphylococcus hominis.

[0101] Example 2: Test of changes in bacterial count with the combination of Citrus unshiu extract and xylitol (1) Test Examples 4 and 5: Cultivation test of Staphylococcus hominis and Staphylococcus aureus

[0102] The amount of Staphylococcus hominis and the amount of Staphylococcus aureus were measured over time in the same manner as in Example 1, except that Ginseng LAH-2-A (Korean ginseng extract, Maruzen Pharmaceuticals) in Table 1 of Example 1 was replaced with Citrus Pepper Extract-J (Citrus Pepper Extract, Maruzen Pharmaceuticals).

[0103] The results are shown in Table 5, Figure 5 and Figure 6.

[0104] [Table 5]

[0105] (2) Test Example 5: Cultivation test of Propionibacterium acnes The ginseng LAH-2-A (Korean ginseng extract, Maruzen Pharmaceuticals) in Table 3 of Example 1 was replaced with Citrus Pepper Extract-J (Citrus Pepper extract, Maruzen Pharmaceuticals), and the change in the amount of Propionibacterium acnes was measured in the same manner as in Example 1.

[0106] The results are shown in Table 6 and FIG.

[0107] [Table 6]

[0108] (3) Discussion From the results of Example 2, it was found that the amount of a specific bacterial cell can be specifically controlled by using xylitol in combination with Citrus unshiu extract. More specifically, it was found that the combined use of xylitol and Citrus unshiu extract can simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus and / or Propionibacterium acnes.

[0109] <Example 3> Coating test (1) Test method (1-1) Subject The subjects were six healthy Japanese men in their 20s to 40s.

[0110] (1-2) Test method (1-2-1) Manufacture of cosmetics containing active ingredients (Examples) and cosmetics not containing active ingredients (Comparative Examples, placebo cosmetics) 1% by mass of ginseng LAH-2-A (Korean ginseng extract, Maruzen Pharmaceuticals) and 1% by mass of xylitol were mixed into 40 mL of PBS to produce an active ingredient-containing cosmetic preparation (Example). Additionally, ginseng LAH-2-A (Korean ginseng extract, Maruzen Pharmaceuticals) was mixed with PBS instead of xylitol to produce a cosmetic composition not containing any active ingredient (comparative example, placebo cosmetic composition).

[0111] (1-2-2) Application of cosmetics 0.2 mL of the cosmetic preparation containing an active ingredient (Example) was applied to one of the left or right cheeks of each subject, and 0.2 mL of the cosmetic preparation not containing an active ingredient (Comparative Example, placebo cosmetic preparation) was applied to the other cheek. Eight hours after the start of application of the cosmetic preparation, the amount of bacteria on the cheek was measured using the following method.

[0112] (1-3) Measurement of bacterial count Before the start of cosmetic application and at the end of the cosmetic application test (8 hours after the start of cosmetic application), the amount of bacteria on each cheek was measured using the following method.

[0113] The amount of bacteria was measured by collecting bacterial flora from the male subjects' cheeks using a cotton swab (Swab method). Next, DNA was extracted from the collected bacterial flora, and quantitative PCR was performed for S. hominis, S. aureus, and P. acnes using the following primer set to measure the 16S rDNA derived from each bacterium.

[0114] Primer set for measuring S. hominis quantity: Forward primer (SEQ ID NO: 1); 5-TAGATGGATCTGAAACAGTAGTAT-3 Reverse primer (SEQ ID NO: 2); 5-CCTTCAACAATACCAAATTCGTC-3 Probe (SEQ ID NO: 3); 5-AGGTGCTTCATGTACTACAAACTCATTG-3

[0115] Primer set for measuring S. aureus quantity: Forward primer (SEQ ID NO: 4); 5-AACTGTTGGCCACTATGAGT-3 Reverse primer (SEQ ID NO: 5); 5-CCAGCATTACCTGTAATCTCG-3

[0116] Primer set for measuring P. acnes quantity: Forward primer (SEQ ID NO: 6); 5-AGGGCTCGTAGGTGGTTG-3 Reverse primer (SEQ ID NO: 7); 5-CCGTTTACAGCGTGGACTA-3 Probe (SEQ ID NO: 8); 5-AGGTGCTTCATGTACTACAAACTCATTG-3

[0117] The 16SrDNA count of the bacteria before application of the cosmetic was set at 1, and the ratio of the 16SrDNA count 8 hours later was calculated to determine the amount of bacteria at the completion of the cosmetic application test. The results were expressed as the mean ± standard deviation (sd) for each subject.

[0118] The results are shown in Table 7 and Figures 8 to 10.

[0119] [Table 7]

[0120] As shown in FIG. 8, even when ginseng extract was used in combination with xylitol, the bacterial count-promoting ability of the ginseng extract for Staphylococcus hominis was maintained.

[0121] In addition, as shown in Figs. 9 and 10, there was no significant difference in the amount of Staphylococcus aureus and Propionibacterium acnes compared to the comparative example. Here, when only ginseng extract was applied, the amount of Staphylococcus aureus and Propionibacterium acnes increased.

[0122] In other words, it was found that the use of a combination of Korean ginseng extract and xylitol can suppress the bacterial counts of Staphylococcus aureus and Propionibacterium acnes. In conclusion, the results of Example 3 show that the amount of a specific bacterial cell can be specifically controlled by using a skin topical composition containing xylitol and ginseng extract. More specifically, it was found that the use of an external skin composition containing xylitol and ginseng extract can simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus and / or Propionibacterium acnes.

[0123] Example 4: Relationship between parameters related to skin condition and Staphylococcus hominis (S. hominis) Various test results supporting the uses of the preferred embodiments of the present invention are shown below.

[0124] The association between the following skin condition parameters and Staphylococcus hominis (S. hominis) was investigated: Unless otherwise specified, the bacterial counts listed below are the number of reads and represent the abundance of Staphylococcus hominis (S. hominis).

[0125] <1> Cultivation of strains In this example, Staphylococcus hominis GTC485 strain (hereinafter, also simply referred to as S. hominis) was used as Staphylococcus hominis. Here, the Staphylococcus hominis GTC485 strain was purchased through the Japanese Society for Bacteriology (Postal Code: 170-0003, Address: Komagome TS Building, 1-43-9 Komagome, Toshima-ku, Tokyo, Japan (Oral Health Association).

[0126] The obtained S. hominis was cultured in BBL-Tripticase Soybean Agar medium (Becton Dickinson, ND, USA) at pH 7.3 under aerobic conditions at 37°C. The cultured cells were harvested, suspended in a 10% skim milk solution, and then vacuum-lyophilized using the L-drying method to obtain S. hominis lyophilized material (approximately 10 11 The freeze-dried S. hominis thus produced was used in the following tests.

[0127] <2> Test method, measurement of S. hominis amount and skin condition

[0128] <2-1> Test method (1) Subjects The subjects were 11 healthy Japanese women in their 30s who did not have any diseases such as atopic dermatitis.

[0129] (2) Test method (2-1) Manufacture of S. hominis-containing cosmetics (Examples) and S. hominis-free cosmetics (Comparative examples, placebo cosmetics) The above freeze-dried S. hominis was suspended in 10 mL of distilled water to form a suspension (S. hominis content: approximately 10 10 CFU / mL) were prepared. 1 mL of the prepared suspension was mixed with 1 mL of lotion (containing polyethylene glycol, dipropylene glycol, glycerin, diglycerin, potassium hydroxide, and water) to prepare a cosmetic containing S. hominis (Example, S. hominis content: approximately 5 × 10 9 CFU / mL) were produced. In addition, a cosmetic preparation not containing S. hominis (comparative example, placebo cosmetic preparation) was produced in the same manner as the cosmetic preparation containing S. hominis, except that freeze-dried skim milk not containing S. hominis was used instead of the freeze-dried S. hominis.

[0130] (2-2) Application of cosmetics The subjects applied 0.2 mL of the cosmetic product containing S. hominis (Example) to one of the left and right cheeks, and 0.2 mL of the cosmetic product not containing S. hominis (Comparative Example, placebo cosmetic product) to the other cheek. 9 CFU) was applied twice a week for one month. One month after starting application of the cosmetic preparation, the skin condition and amount of S. hominis on the cheeks were measured using the following methods.

[0131] <2-2> Measurement of S. hominis quantity and skin condition (1) Measurement and evaluation of the amount of S. hominis in the cheek The amount of S. hominis on each cheek was measured using the following method before the start of cosmetic application, during the cosmetic application period, and at the end of the cosmetic application test (one month after the start of cosmetic application).

[0132] Bacterial flora was collected from the cheeks of female subjects using a sticker or cotton swab (Swab method). DNA was then extracted from the collected bacterial flora, and S. hominis was analyzed by OTU (Operational Taxonomic Unit) analysis. The amount of S. hominis was measured by counting the number of reads belonging to each OTU.

[0133] The amount of S. hominis for each subject at the time of each cosmetic application test was calculated by setting the number of S. hominis leads before application of the cosmetic as 1, and calculating the ratio of leads one week, two weeks, three weeks, and one month after application. The results were expressed as the mean ± standard error (se) for each subject (N = 11). Statistical analysis was performed based on two-way analysis of variance (*P < 0.05).

[0134] (2) Measurement and evaluation of the number of noticeable pores Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the number of noticeable pores on the cheeks was evaluated using the following method.

[0135] First, a skin image was taken using a skin image analysis counseling system (Canfield, VISIA-EVOLUTION), and the number of noticeable pores of the subject was counted by image analysis. The difference between the number of pores measured at the end of the cosmetic application test and the number of pores before the start of cosmetic application was calculated, and this was taken as the change in the number of noticeable pores (Δnumber of noticeable pores).

[0136] Here, a larger value of the change in the number of noticeable pores (Δnumber of noticeable pores) indicates a greater decrease in the number of noticeable pores. The results were expressed as the mean ± standard error (se) of the change in the number of noticeable pores for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

[0137] (3) Measurement and evaluation of melanin index Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the melanin index in the cheeks was evaluated by the following method.

[0138] First, the absorbance (A) was measured using a spectrophotometer (Konica Minolta Sensing Co., Ltd., CM2600d), and then the melanin index (MI) was calculated using the formula (MI = A 640 -A 670 The melanin index of the subjects was measured by calculating the melanin index using the formula (F(x,y)) and the Feather's formula. The difference between the measured melanin index at the end of the cosmetic application test and the melanin index before the start of cosmetic application was calculated and used as the change in melanin index (Δmelanin index).

[0139] Here, a larger value of the change in melanin index (Δmelanin index) indicates a greater decrease in the melanin index. The results were expressed as the mean ± standard error (se) for each subject (N = 11) based on the Wilcoxon signed rank test (*P < 0.05).

[0140] (4) Measurement and evaluation of the number of wrinkles Before the start of cosmetic application and at the end of the cosmetic application test (one month after the start of cosmetic application), the number of noticeable wrinkles on the cheeks was evaluated using the following method.

[0141] First, a skin image was taken using a skin image analysis counseling system (VISIA-EVOLUTION, manufactured by Canfield) and the number of wrinkles of the subject was counted by image analysis. The difference between the number of wrinkles measured at the end of the cosmetic application test and the number of wrinkles before the start of cosmetic application was calculated and used as the change in the number of wrinkles (Δnumber of wrinkles).

[0142] Here, a larger value of the change in the number of wrinkles (Δnumber of wrinkles) indicates a greater reduction in the number of wrinkles. In addition, the results were expressed as the mean ± standard error (se) of the change in the number of wrinkles (Δnumber of wrinkles) for each subject (N=11) based on the Wilcoxon signed rank test (*P<0.05).

[0143] <2-3>Result The results are shown in Tables 8 and 9 and in FIGS.

[0144] [Table 8]

[0145] [Table 9]

[0146] As shown in Table 8 and FIG. 11, it was found that the amount of S. hominis increased in subjects who continuously used cosmetics containing S. hominis.

[0147] 12, the change in the number of noticeable pores (Δ number of noticeable pores) was greater on the cheeks of subjects who had continuously used cosmetics containing S. hominis compared to the cheeks of subjects who had used cosmetics not containing S. hominis. In other words, it was found that the number of noticeable pores was reduced on the cheeks of subjects who had continuously used cosmetics containing S. hominis compared to the cheeks of subjects who had used cosmetics not containing S. hominis.

[0148] From the above, it was found that S. hominis has the effect of preventing or improving skin conditions caused by an increase in the number of noticeable pores.

[0149] In addition, as shown in Table 9 and Figure 13, the subject who continuously used the cosmetic preparation containing S. hominis had a larger change in melanin index (Δ melanin index) compared to the cheeks of the subject who used the cosmetic preparation not containing S. hominis. In other words, it was found that the melanin index of the cheeks of the subject who continuously used the cosmetic preparation containing S. hominis was reduced compared to the cheeks of the subject who used the cosmetic preparation not containing S. hominis.

[0150] From the above, it was found that S. hominis has the effect of preventing or improving skin conditions caused by increased melanin levels.

[0151] As shown in Table 9 and Figure 14, the change in the number of wrinkles (Δ number of wrinkles) was greater on the cheeks of subjects who had continuously used cosmetics containing S. hominis compared to the cheeks of subjects who had used cosmetics not containing S. hominis. In other words, it was found that the number of wrinkles was reduced on the cheeks of subjects who had continuously used cosmetics containing S. hominis compared to the cheeks of subjects who had used cosmetics not containing S. hominis.

[0152] From the above, it was found that S. hominis has the effect of preventing or improving skin conditions caused by an increase in the number of wrinkles.

[0153] Furthermore, as shown in the above-mentioned test, by using the ginseng extract and / or the tangerine extract in combination with xylitol, a bacterial count promoting effect of S. hominis can be obtained.

[0154] That is, by using a combination of ginseng extract and / or Citrus Pepper extract and further xylitol, it is possible to provide a composition that exhibits the above-mentioned skin condition improving effects in a complex manner.

[0155] Example 5: Test on the change in bacterial count with the aid of Thamnoides extract

[0156] (1) Preparation of bacterial suspension First, Staphylococcus aureus was cultured in 802 medium at pH 7.0 (see the table below).

[0157] The OD660 of the cultured bacterial suspension was measured using a turbidity meter (NovaspecII (Amercham Pharmacia Biotech)), and the bacterial concentration was calculated.

[0158] (2) Test methods and results The bacterial suspension prepared by the above-mentioned method was added to the example medium and comparative example medium shown in Table 10 so that the total volume was 5 mL. The amount of bacteria in the medium after adding bacteria was 5 × 10 7 cells.

[0159] [Table 10]

[0160] After the addition, shaking culture was carried out under aerobic conditions at 37°C.

[0161] From the start of the shaking culture, OD660 was measured every hour using a turbidity meter (NovaspecII (Amercham Pharmacia Biotech)). The change in OD660 measurement value (OD660Δinitial value) was calculated by subtracting the OD660 measurement value at the measured time from the OD660 measurement value at the start of shaking culture.

[0162] The results were expressed as the mean ± standard deviation (sd) of N=3. Statistical analysis was performed based on the t-test (*P<0.05).

[0163] The results are shown in Table 11 and Figure 15.

[0164] [Table 11]

[0165] (3) Discussion From the results in Table 11, it was found that the extract of Tenebrio gracilis has an inhibitory effect on the bacterial count of Staphylococcus aureus.

[0166] Example 6: Test on the change in bacterial count by combining Korean ginseng extract and / or Chinese chimpi extract with Chinese ginger extract

[0167] (1) Test methods and results The bacterial suspension prepared by the above-mentioned method was added to the example medium and comparative example medium shown in Table 12 so that the total volume was 5 mL. The amount of bacteria in the medium after adding bacteria was 5 × 10 7 cells.

[0168] [Table 12]

[0169] After the addition, shaking culture was carried out under aerobic conditions at 37°C.

[0170] From the start of the shaking culture, OD660 was measured every hour using a turbidity meter (NovaspecII (Amercham Pharmacia Biotech)). The change in OD660 measurement value (OD660Δinitial value) was calculated by subtracting the OD660 measurement value at the measured time from the OD660 measurement value at the start of shaking culture.

[0171] (2) Results The results are shown in Table 13 and Figures 16 to 21. The results were expressed as the mean ± standard deviation (sd) of N=3. Statistical analysis was performed based on the t-test (*P<0.05).

[0172] [Table 13]

[0173] (3) Discussion The results in Table 13 show that the combined use of ginseng extract and L. arbutifolia extract can specifically control the amount of a specific fungus. More specifically, it was found that the combined use of ginseng extract and ginseng extract can simultaneously promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus.

[0174] The results in Table 13 show that the combined use of Citrus unshiu extract and Lactobacillus subhirtella extract makes it possible to specifically control the amount of specific fungal cells. More specifically, it was found that the combined use of Citrus Fruit Extract and Scutellaria Baicalensis Extract can promote the bacterial count of Staphylococcus hominis and suppress the bacterial count of Staphylococcus aureus. [Industrial Applicability]

[0175] The present invention is applicable to cosmetics.

Claims

1. Korean ginseng extract and / or Chinese chimpi extract, xylitol and / or tallow extract as active ingredients; The content of the Korean ginseng extract and / or the Citrus recutita extract in the bacterial quantity regulator is 0.02% by mass or more and 2% by mass or less, In the case where the xylitol is contained, the content of the xylitol in the bacterial quantity regulator is 0.5% by mass or more and 2% by mass or less, In the case where the bacteria amount regulator contains the Tithonia gracilis extract, the content of the Tithonia gracilis extract in the bacteria amount regulator is 0.02% by mass or more and 2% by mass or less. A bacterial load regulator for promoting the bacterial load of Staphylococcus hominis.

2. When the bacteria quantity regulator contains the ginseng extract, the content ratio of the ginseng extract to the xylitol and / or the Tilia arborescens extract in the bacteria quantity regulator is 1:1.5 to 1:0.5; The bacterial quantity regulator according to claim 1, wherein when the bacterial quantity regulator contains the Citrus unshiu extract, the content ratio of the Citrus unshiu extract to the xylitol and / or the Citrus gracilis extract in the bacterial quantity regulator is 1:2 to 1:0.

5.

3. The Korean ginseng extract and / or the Chinese chimpi extract, The xylitol, Contains as an active ingredient The bacterial quantity regulator according to claim 1 or 2, which is for promoting the bacterial quantity of Staphylococcus hominis and suppressing the bacterial quantities of Staphylococcus aureus and / or Propionibacterium acnes.

4. The Korean ginseng extract and / or the Chinese chimpi extract, The tallow extract, Contains as an active ingredient The bacterial amount regulator according to any one of claims 1 to 3, for promoting the bacterial amount of Staphylococcus hominis and suppressing the bacterial amount of Staphylococcus aureus.

5. A bacterial load regulator for external application to the skin for promoting the bacterial load of Staphylococcus hominis, comprising the bacterial load regulator according to any one of claims 1 to 4.

Images